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Background: Ticagrelor increases adenosine plasma levels and coronary blood flow in response to intravenous adenosine administration. 
It has been suggested that ticagrelor may influence endothelial function in patients with coronary artery disease (CAD). We aimed to 
assess the differential effect of ticagrelor compared to prasugrel on endothelial function in patients with CAD.
methods: This is a prospective, randomized study with a crossover design, in patients with stable CAD under prasugrel maintenance dose 
(MD) 10mg once a day for at least a 3-month period. Eligible patients are randomized in a 1:1 ratio to either ticagrelor 90 mg twice daily 
or prasugrel 10 mg once daily for 15 days with a crossover directly to the alternate treatment for another 15 days. Endothelial function 
is assessed by Peripheral Arterial Tonometry (EndoPat 2000 system, Itamar Medical, Caesarea, Israel) at Day 0 (day of randomization), 
Day 15 and Day 30. Reactive Hyperemia Index (RHI) and Augmentation index (AI) are calculated by automated software. Endothelial 
dysfunction (ED) was defined as RHI<1.67.
results:  We recruited 16 patients with complete Day 30 data. Patients’ characteristics, baseline RHI and AI did not differ between 
ticagrelor and prasugrel arm. RHI at the end of the two treatment periods did not differ between ticagrelor and prasugrel: 1.80 (95% CI 
1.59-2.00) vs 1.90 (95% CI 1.69-2.11), p=0.5. ED rate did not differ significantly between ticagrelor and prasugrel: 31.2% vs 43.8%, p=0.7. 
AI at the end of the two treatment periods did not differ significantly between ticagrelor and prasugrel: 21.75 (95% CI 12.5-31.0) vs 20.44 
(95% CI 11.19-29.69), p=0.8.
Conclusion:  Endothelial function was not significantly altered following ticagrelor compared to prasugrel MD treatment, in patients with 
stable CAD, as assessed with Peripheral Arterial Tonometry.
